In addition, Kaplan-Meier analyses further demonstrated that the 5-year OS and RFS probabilities were both above 80% in CD4+ T cells ≤16 (median expression levels in cancer tissue) cancer patients, whereas only about 50% of OS and RFS in CD4+ T cells > 16 patients (Figure 5A). The gene discussed is CD4; the disease is cancer.